tetano
Editor, Senior Moderator
Front Immunol
. 2026 Jan 15:16:1724625.
doi: 10.3389/fimmu.2025.1724625. eCollection 2025.
SARS-CoV-2 spike antibodies cross-react with dengue virus and enhance infection in vitro and in vivo
Kamini Jakhar[SUP] #[/SUP][SUP] 1 [/SUP], Sudipta Sonar[SUP] #[/SUP][SUP] 1 [/SUP], Gagandeep Singh[SUP] 2 [/SUP], Tejeswara Rao Asuru[SUP] #[/SUP][SUP] 3 [/SUP], Garima Joshi[SUP] #[/SUP][SUP] 3 [/SUP], Nisha Beniwal[SUP] 1 [/SUP], Tania Sarkar[SUP] 1 [/SUP], Mahima Tiwari[SUP] 1 [/SUP], Jaskaran Kaur[SUP] 1 [/SUP], Deepak Kumar Rathore[SUP] 4 [/SUP], Banwari Lal[SUP] 1 [/SUP], Sandeep Kumar[SUP] 1 [/SUP], Puneet Srivastav[SUP] 1 [/SUP], Satendra Kumar[SUP] 1 [/SUP], Vikas Phagna[SUP] 1 [/SUP], Sushma Mithina[SUP] 1 [/SUP], Lokesh Kumar[SUP] 1 [/SUP], Vishal Gupta[SUP] 1 5 [/SUP], Pallavi Kshetrapal[SUP] 6 [/SUP], Savita Singh[SUP] 6 [/SUP], Nitya Wadhwa[SUP] 6 [/SUP], Ramachandran Thiruvengadam[SUP] 6 [/SUP], Sreevatsan Raghavan[SUP] 6 [/SUP], Mudita Gosain[SUP] 6 [/SUP], Tripti Shrivastava[SUP] 1 [/SUP], Sankar Bhattacharyya[SUP] 1 [/SUP], Shailendra Asthana[SUP] 2 [/SUP], Prasenjit Guchhait[SUP] 3 [/SUP], Shailendra Mani[SUP] 1 [/SUP]
Affiliations
The presence of non-neutralizing antibodies of any dengue serotype increases the severity of subsequent infection by other dengue serotypes. During the SARS-CoV-2 pandemic, the number of symptomatic dengue cases increased in India. We found that antibodies isolated from convalescent plasma from COVID-19 patients enhances DENV2 infection in vitro. CR3022, an antibody against the SARS-CoV-2 spike protein, also elevated DENV2 infection in vitro. In silico protein-protein interactions between spike antibodies and the DENV2 E-protein revealed significant interactions. Likewise, few monoclonal/polyclonal antibodies against SARS-CoV-2 have shown increased dengue infection in vitro. Importantly, AG129 mice infected with SARS-CoV-2 three weeks prior to DENV2 infection showed elevated dengue pathogenesis. This highlights the possibility of elevated infection and symptomatic dengue disease in COVID-19 survivors.
Keywords: AG129 mice model; SARS-CoV-2; antibody-dependent enhancement; cross-reactivity; dengue virus.
. 2026 Jan 15:16:1724625.
doi: 10.3389/fimmu.2025.1724625. eCollection 2025.
SARS-CoV-2 spike antibodies cross-react with dengue virus and enhance infection in vitro and in vivo
Kamini Jakhar[SUP] #[/SUP][SUP] 1 [/SUP], Sudipta Sonar[SUP] #[/SUP][SUP] 1 [/SUP], Gagandeep Singh[SUP] 2 [/SUP], Tejeswara Rao Asuru[SUP] #[/SUP][SUP] 3 [/SUP], Garima Joshi[SUP] #[/SUP][SUP] 3 [/SUP], Nisha Beniwal[SUP] 1 [/SUP], Tania Sarkar[SUP] 1 [/SUP], Mahima Tiwari[SUP] 1 [/SUP], Jaskaran Kaur[SUP] 1 [/SUP], Deepak Kumar Rathore[SUP] 4 [/SUP], Banwari Lal[SUP] 1 [/SUP], Sandeep Kumar[SUP] 1 [/SUP], Puneet Srivastav[SUP] 1 [/SUP], Satendra Kumar[SUP] 1 [/SUP], Vikas Phagna[SUP] 1 [/SUP], Sushma Mithina[SUP] 1 [/SUP], Lokesh Kumar[SUP] 1 [/SUP], Vishal Gupta[SUP] 1 5 [/SUP], Pallavi Kshetrapal[SUP] 6 [/SUP], Savita Singh[SUP] 6 [/SUP], Nitya Wadhwa[SUP] 6 [/SUP], Ramachandran Thiruvengadam[SUP] 6 [/SUP], Sreevatsan Raghavan[SUP] 6 [/SUP], Mudita Gosain[SUP] 6 [/SUP], Tripti Shrivastava[SUP] 1 [/SUP], Sankar Bhattacharyya[SUP] 1 [/SUP], Shailendra Asthana[SUP] 2 [/SUP], Prasenjit Guchhait[SUP] 3 [/SUP], Shailendra Mani[SUP] 1 [/SUP]
Affiliations
- PMID: 41624894
- PMCID: PMC12852381
- DOI: 10.3389/fimmu.2025.1724625
The presence of non-neutralizing antibodies of any dengue serotype increases the severity of subsequent infection by other dengue serotypes. During the SARS-CoV-2 pandemic, the number of symptomatic dengue cases increased in India. We found that antibodies isolated from convalescent plasma from COVID-19 patients enhances DENV2 infection in vitro. CR3022, an antibody against the SARS-CoV-2 spike protein, also elevated DENV2 infection in vitro. In silico protein-protein interactions between spike antibodies and the DENV2 E-protein revealed significant interactions. Likewise, few monoclonal/polyclonal antibodies against SARS-CoV-2 have shown increased dengue infection in vitro. Importantly, AG129 mice infected with SARS-CoV-2 three weeks prior to DENV2 infection showed elevated dengue pathogenesis. This highlights the possibility of elevated infection and symptomatic dengue disease in COVID-19 survivors.
Keywords: AG129 mice model; SARS-CoV-2; antibody-dependent enhancement; cross-reactivity; dengue virus.